04.09.26 -- Cell And Gene Therapy CDMOs: On The Path To $75 Billion In Services?

Comparing plasmid DNA to enzymatically produced DNA shows how enzymatic methods cut manufacturing costs, speed production, and boost efficiency for large‑scale AAV gene therapy.

This high-level overview examines the full gene therapy lifecycle, covering critical milestones in process development, regulatory engagement, and manufacturing strategies for success.

Unlock the knowledge and strategies you need to navigate the complexities of CGT outsourcing and accelerate the success of your cell and gene therapy projects.

Optimize gene therapy manufacturing by utilizing specialized microbial platforms that preserve ITR integrity and reduce variability, resulting in scalable and cost-effective DNA production.

Modern AAV manufacturing demands precise capsid characterization to distinguish empty, partial, and full particles, as regulators now require rigorous purity and potency control for clinical safety.

By integrating perfusion into upstream manufacturing, see how this approach has achieved up to a fivefold increase in productivity, delivering titers that significantly exceed current industry benchmarks.

Reduce complexity and shorten development timelines by utilizing optimized AAV transfection platforms designed to simplify analytical workflows and accelerate your regulatory filing.

Explore a plasmid‑free AAV platform delivering higher yields, cleaner product profiles, lower costs, and scalable manufacturing from early development to commercial production across serotypes.

Robust formulations protect long‑term biologic stability, safety, and efficacy by combining scientific insight, early modeling, and process‑aware development to handle variability.